Pirfenidone

SKU: orb1305557

Description

Pirfenidone

Research Area

Immunology & Inflammation, Infectious Disease & Virology, Pharmacology & Drug Discovery, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 53179-13-8
• MW: 185.22
• Purity: 99.80%
• Formula: C₁₂H₁₁NO
• SMILES: O=C1N(C=C(C)C=C1)C2=CC=CC=C2
• Target: TGF-beta/Smad,CCR
• Solubility: H2O:25 mg/mL (134.97 mM);5% DMSO+95% Saline:1.86 mg/mL (10.04 mM);DMSO:237.5 mg/mL (1282.26 mM)

Bioactivity

• Target IC50:
  HFL1 cells:0.71 μM|NIH3T3 cells:454 μM|MRC5 cells:14.44 mM
• In Vivo:
  METHODS: To examin the effect of Pirfenidone on pulmonary fibrosis, Pirfenidone (30-100 mg/kg, 0.5% carboxymethylcellulose) was administered orally three times a day for 42 days to ICR mice with bleomycin-induced pulmonary fibrosis. Results: Pirfenidone inhibited pulmonary inflammatory edema and significantly suppressed pulmonary fibrosis. Durin the development of bleomycin-induced pulmonary fibrosis in mice, Pirfenidone exerted its antifibrotic effects by regulatin the levels of lung IFN-γ, bFGF and TGF-β1.
• In Vitro:
  METHODS: Mouse macrophage-like cell line RAW264.7 was treated with lipopolysaccharide (1 µg/mL) and Pirfenidone (30-300 µg/mL) for 8 h. TNF-α was detected by ELISA assay. Results: Exposure of RAW264. Cells to Pirfenidone significantly inhibited cell-associated and secreted TNF-α levels. METHODS: Three stromal cell lines from control lungs and three cell lines derived from idiopathic pulmonary fibrosis (IPF) were treated with Pirfenidone (0.1-1 mM for 6 dayss and cell viability was measured by MTT assay. Results: Pirfenidone inhibited cell proliferation in a dose-dependent manner. On day 6 of 1 mM Pirfenidone treatment, proliferation was reduced to 47% for control cells and 42% for IPF cells.
• Cell Research:
  Pirfenidone (PFD) is dissolved in DMSO and stored, and then diluted with appropriate media before us. HLECs are seeded in 96-well plates ( × 0^4 cells/well) for 24 hours in α-MEM/10% FBS/1%NEAA, and are cultured in stationary tubes in serum-free medium for 24 hours. and the The culture medium is removed and cells are bathed in α-MEM with 10% FBS and 1% NEAA supplemented with 0, 0.01, 0.1, 0.2, 0.3, 0.5, or 1 mg mL Pirfenidone for 0, 4, 12, 24, 48, or 72 hours. After incubation with 180 μL α-MEM and 20 μL of 5 mg mL MTT for 4 hours at 37℃he MTT solution is discarded the Formosan precipitates are dissolved in 180 μL DMSO by agitatin the dishes for 10 minutes at 200 rpm on an orbital shaker the absorbance at 490 nM in Each well is read with a micro plate reader. We further examine the effects of PFD by refinin the concentration at 0.2, 0.25, 0.3, 0.4, 0.5 and 0.6 mg mL usin the MTT assa.

Storage & Handling

• Storage: keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Pirfenidone, Smad, S 7701, S7701, S-7701, S-7701,AMR-69, TGF-b/Smad, TGFb, TGF-β/Smad, TGFβ, TGF-beta/Smad, TGFbeta, TGF-beta, TGFbeta/Smad, Transforming growth factor beta, TGFβ2, CC chemokine receptor, AMR 69, AMR69, AMR-69, CCR, inhibit, Inhibitor

Compound Identifiers

PubChem CID

40632